Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.46 |
| ▸ | PPARA | Q07869 | 10/20 | 0.46 |
| ▸ | PPARD | Q03181 | 7/20 | 0.46 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | ACLY | P53396 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18851080 | 0.88 | PPARG (0.48) | PPARGPPARAPPARDALDH3A1MTNR1B | |
| SCHEMBL18824246 | 0.84 | PPARG (0.47) | PPARGPPARAPPARDALDH3A1MTNR1B | |
| SCHEMBL18850582 | 0.84 | PPARG (0.42) | PPARGPPARAPPARDALDH3A1MTNR1B | |
| SCHEMBL18850580 | 0.82 | PPARG (0.43) | PPARGPPARAPPARDALDH3A1MTNR1B | |
| SCHEMBL18824208 | 0.78 | NOD2 (0.47) | PPARGPPARAPPARDALDH3A1MTNR1B | |
| SCHEMBL378955 | 0.76 | CA12 (0.51) | PPARGPPARAPPARDTSHRMAPT | |
| SCHEMBL17433482 | 0.74 | PPARG (0.43) | PPARGPPARAPPARDACLYSMN1; SMN2 | |
| SCHEMBL3525871 | 0.73 | PPARG (0.59) | PPARGPPARAPPARDMTNR1B | |
| SCHEMBL18851072 | 0.73 | ACLY (0.40) | ALDH3A1ACLYGAA | |
| SCHEMBL18851384 | 0.72 | ALDH3A1 (0.39) | ALDH3A1ACLYGAATSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180312493-A1 | Antibiotic Compounds, Pharmaceutical Formulations Thereof And Methods And Uses Therefor | CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2018-11-01 | — | — | US | disclosed |
| WO-2017075694-A1 | ANTIBIOTIC COMPOUNDS, PHARMACEUTICAL FORMULATIONS THEREOF AND METHODS AND USES THEREFOR | SIMON FRASER UNIVERSITY (CA) | 2017-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312493-A1 | Antibiotic Compounds, Pharmaceutical Formulations Thereof And Methods And Uses Therefor | UGT1A8, CYP2C8, CXCL8 | PPARG 1499/4885PPARA 2745/4885PPARD 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.